Progression of Disease Severity Score (DSS) and Disease Activity Score (DAS) over time.
| DSS | Percentage of Patients (n) with DSS ≥ 1 | |||
|---|---|---|---|---|
| Subtype | Baseline | Month 30 | p* | |
| General | dcSSc | 33.3 (28/84) | 18.8 (6/32) | 0.257 |
| lcSSc | 16.7 (46/276) | 25.5 (27/106) | 0.007 | |
| lSSc | 19.2 (14/73) | 7.1 (1/14) | 0.596 | |
| Peripheral vascular | dcSSc | 72.9 (62/85) | 90.6 (29/32) | 0.708 |
| lcSSc | 66.3 (183/276) | 64.2 (68/106) | 0.772 | |
| lSSc | 41.1 (30/73) | 50.0 (7/14) | > 0.999 | |
| Skin | dcSSc | 100 (86/86) | 100 (32/32) | > 0.999 |
| lcSSc | 100 (265/265) | 91.7 (88/96) | > 0.999 | |
| lSSc | 0 (0/73) | 57.1 (8/14) | 0.002 | |
| Joint/tendon | dcSSc | 72.6 (61/84) | 64.5 (20/31) | 0.582 |
| lcSSc | 28.7 (79/275) | 30.8 (32/104) | > 0.999 | |
| lSSc | 11.0 (8/73) | 28.6 (4/14) | > 0.999 | |
| Muscle | dcSSc | 22.4 (19/85) | 18.8 (6/32) | 0.732 |
| lcSSc | 7.6 (21/277) | 2.9 (3/103) | > 0.999 | |
| lSSc | 5.5 (4/73) | 0.0 (0/14) | > 0.999 | |
| GI tract | dcSSc | 48.2 (40/83) | 51.6 (16/31) | 0.795 |
| lcSSc | 29.7 (82/276) | 34.6 (36/104) | 0.456 | |
| lSSc | 16.7 (12/72) | 14.3 (2/14) | > 0.999 | |
| Lung | dcSSc | 82.1 (69/84) | 82.1 (23/28) | > 0.999 |
| lcSSc | 76.0 (209/275) | 83.7 (87/104) | 0.065 | |
| lSSc | 53.4 (39/73) | 42.9 (6/14) | > 0.999 | |
| Heart | dcSSc | 16.5 (14/85) | 13.3 (4/30) | 0.731 |
| lcSSc | 11.6 (32/275) | 9.6 (10/104) | > 0.999 | |
| lSSc | 11.0 (8/73) | 0.0 (0/13) | > 0.999 | |
| Kidney | dcSSc | 10.7 (9/84) | 0.0 (0/32) | 0.492 |
| lcSSc | 2.2 (6/277) | 3.8 (4/106) | 0.683 | |
| lSSc | 1.4 (1/73) | 7.1 (1/14) | > 0.999 | |
| Percentage of Patients (n) with DAS ≥ 3 | ||||
| DAS | dcSSc | 57.6 (49/85) | 40.6 (13/32) | 0.145 |
| lcSSc | 21.9 (61/278) | 27.4 (29/106) | 0.282 | |
| lSSc | 11.1 (8/72) | 7.1 (1/14) | > 0.999 | |
↵* Fisher’s exact test. Data in bold type are considered statistically significant. SSc: systemic sclerosis; lSSc: limited SSc. lcSSc: limited cutaneous SSc; dcSSc: diffuse cutaneous SSc; GI: gastrointestinal.